title: Stopping a trial early in oncology: for patients or for industry?
authors.forename: P
authors.initials: P
authors.lastname: Bradbury
authors.forename: R
authors.initials: R
authors.lastname: Meyer
authors.forename: J
authors.initials: J
authors.lastname: Pater
authors.forename: D
authors.initials: D
authors.lastname: Tu
authors.forename: L
authors.initials: L
authors.lastname: Seymour
authors.forename: L
authors.initials: L
authors.lastname: Shepherd
authors.forename: E
authors.initials: E
authors.lastname: Eisenhauer
mesh_terms: D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D004345:Drug Industry; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D016019:Survival Analysis; D016896:Treatment Outcome